Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Кафедра психиатрии медфакультета Университета, Париж, Франция
Список исп. литературыСкрыть список
1. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MT1- and MT2-receptors. Naunyn Schmiedebergs. Arch Pharmacol 2003; 367: 553–61.
2. Avery DH, Wildschiodtz G, Rafaelsen OJ. Nocturnal temperature in affective disorder. J Affect Disord 1982; 4: 61–71.
3. Barden N, Shink E, Labbe M et al. Antidepressant action of agomelatine (S20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 908–16.
4. Benedetti F, Barbini B, Fulgosi MC et al. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry 2005; 66: 1535–40.
5. Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S20098) in the learned helplessness model. Behav Pharmacol 2006; 17: 703–13.
6. Blier P, Keller MB, Pollack MH et al. Preventing recurrent depression: long-term treatment for major depressive disorder. Prim Care Companion. J Clin Psychiatry 2007; 9: 214–23.
7. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29: 126–33.
8. Bunney JN, Potkin SE. Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 2008; 86: 23–32.
9. Claustrat B, Chazot G, Brun J et al. A chronobiological study of melatonin and Cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984; 19: 1215–28.
10. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of major depressive disorder. Am J Psychiatry 1998; 155: 1119–21.
11. Emens J, Lewy A, Kinzie JM et al. Circadian misalignment in major depressive disorder. Psychiatry Res 2009; 168: 259–61.
12. Fava M, Mallinckrodt CH, Detke MJ et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004; 65: 521–30.
13. Fitzgerald LR, Reed JE. Melatonin agonists for the treatment of sleep disorders and major depression. Ann Rep Med Chem 2004; 39: 25–37.
14. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders An opportunity for prevention? JAMA 1989; 262: 1479–84.
15. Goodwin GM, Emsley R, Rembry S, Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128–37.
16. Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open-label study. Clin Sleep Med 2009; 5: 28–33.
17. Hampp G, Ripperger JA, Houben T et al. Regulation of monoamine oxidase A by circadian-clock components implies clock influence on mood. Curr Biol 2008; 18: 678–83.
18. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338–43.
19. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest–activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109–20.
20. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine. A new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009; 10: 117–26.
21. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100.
22. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329–33.
23. Krauchi K, Cajochen C, Mori D et al. Early evening melatonin and S20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272: 1178–88.
24. Kripke DF, Mullaney DJ, Klauber MR et al. Controlled trial of bright light for non seasonal major depressive disorders. Biol Psychiatry 1992; 31: 119–34.
25. Kripke DF, Nievergelt CM, Joo E et al. Circadian polymorphisms associated with affective disorders. J Circadian Rhythms 2009; 7: 2.
26. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32.
27. Loo H, Hale A and D\'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47.
28. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C-receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64.
29. Molteni R, Calabrese F, Pisoni S et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010; 11: 148–53.
30. Molteni R, Soumier A, Mallei A et al. Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C-properties. Eur Neuropsychopharmacol 2009; 19 (Suppl. 3): 441.
31. Montgomery SA. Why do we need new and better antidepressants? Int Clin Psychopharmacol 2006; 21 (Suppl. 1): 1–10.
32. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 283–91.
33. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80.
34. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163: 101–8.
35. Olie IP, Kasper S. Efficacy of agomelatine, a MT1/MT2-receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73.
36. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacol 2003; 28: 694–703.
37. Quera Salva MA, Vanier B, Laredo J et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10: 691–6.
38. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007; 22 (Suppl. 2): 9–14.
39. Redman JR, Guardiola-Lemaitre B, Brown M et al. Dose dependent effects of S20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacol 1995; 118: 385–90.
40. Sawada N, Uchida H, Suzuki T et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009; 9: 38.
41. Schulz P, Steimer T. Neurobiology of circadian systems. CNS Drugs 2009; 23 (Suppl. 2): 3–13.
42. Souetre E, Salvati E, Pringuey D et al. The circadian rhythm of plasma thyrotropin in depression and recovery. Chronohiol 1986; 3: 197–205.
43. Souetre E, Condito M, Salvati E et al. 24-hour profile of plasma norepinephrine in affective disorders. Neuropsychobiol 1986; 16: 1–8.
44. Soumier A, Banasr M, Lortet S et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus Neuropsychopharmacol 2009; 34: 2390–403.
45. Thase ME. Antidepressant treatment of the depressed patient with insomnia. Clin Psychiatry 1999; 60 (Suppl. 17): 28–31.
46. Turek FW. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 2007; 22 (Suppl. 2): l–8.
47. Weil ZM, Hotchkiss AK, Gatien ML et al. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 2006; 68: 425–9.
48. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hyphothesis. Am J Psychiatry 1990; 147: 14–21.